These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 30940296)

  • 41. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
    Cusi K; Orsak B; Bril F; Lomonaco R; Hecht J; Ortiz-Lopez C; Tio F; Hardies J; Darland C; Musi N; Webb A; Portillo-Sanchez P
    Ann Intern Med; 2016 Sep; 165(5):305-15. PubMed ID: 27322798
    [TBL] [Abstract][Full Text] [Related]  

  • 42. State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis.
    Cho Y; Lee YH
    Endocrinol Metab (Seoul); 2022 Feb; 37(1):38-52. PubMed ID: 35255600
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis.
    Polyzos SA; Kang ES; Boutari C; Rhee EJ; Mantzoros CS
    Metabolism; 2020 Oct; 111S():154203. PubMed ID: 32151660
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Emerging therapeutic targets for NASH: key innovations at the preclinical level.
    Horn P; Newsome PN
    Expert Opin Ther Targets; 2020 Mar; 24(3):175-186. PubMed ID: 32053033
    [No Abstract]   [Full Text] [Related]  

  • 45. The Role of Metabolic Surgery in Non-alcoholic Steatohepatitis Improvement.
    Caravatto PP; Cohen R
    Curr Atheroscler Rep; 2017 Oct; 19(11):45. PubMed ID: 28986720
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Simultaneous living donor liver transplant with sleeve gastrectomy for metabolic syndrome and NASH-related ESLD-First report from India.
    Kumar S; Khandelwal N; Kumar A; Yadav K; Sharma S; Sable S; Chauhan A; Kapoor S; Varma V; Palep J; Kumaran V
    Indian J Gastroenterol; 2017 May; 36(3):243-247. PubMed ID: 28560633
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [What is the position of bariatric surgery in the treatment of non-alcoholic steatohepatitis?].
    NtandjaWandji LC; Baud G; Lassailly G
    Presse Med; 2019 Dec; 48(12):1502-1506. PubMed ID: 31757736
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment options for nonalcoholic steatohepatitis - a safety evaluation.
    Issa D; Wattacheril J; Sanyal AJ
    Expert Opin Drug Saf; 2017 Aug; 16(8):903-913. PubMed ID: 28641031
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.
    Cernea S; Cahn A; Raz I
    Expert Rev Clin Pharmacol; 2017 May; 10(5):535-547. PubMed ID: 28276774
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
    Caldwell S
    Clin Mol Hepatol; 2017 Jun; 23(2):103-108. PubMed ID: 28494529
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel Pharmacotherapy Options for NASH.
    Ratziu V
    Dig Dis Sci; 2016 May; 61(5):1398-405. PubMed ID: 27003143
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions.
    Cusi K
    Liver Int; 2020 Feb; 40 Suppl 1():82-88. PubMed ID: 32077613
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design.
    Zang S; Chen J; Song Y; Bai L; Chen J; Chi X; He F; Sheng H; Wang J; Xie S; Xie W; Yang Y; Zhang J; Zheng M; Zou Z; Wang B; Shi J;
    Adv Ther; 2018 Feb; 35(2):218-231. PubMed ID: 29411270
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis.
    Ipsen DH; Rolin B; Rakipovski G; Skovsted GF; Madsen A; Kolstrup S; Schou-Pedersen AM; Skat-Rørdam J; Lykkesfeldt J; Tveden-Nyborg P
    Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):704-713. PubMed ID: 29953740
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
    Kim SK; Kim KI; Kim SR
    Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.
    Ganesh S; Rustgi VK
    Clin Liver Dis; 2016 May; 20(2):351-64. PubMed ID: 27063274
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevalence of nonalcoholic steatohepatitis in Japanese patients with morbid obesity undergoing bariatric surgery.
    Seki Y; Kakizaki S; Horiguchi N; Hashizume H; Tojima H; Yamazaki Y; Sato K; Kusano M; Yamada M; Kasama K
    J Gastroenterol; 2016 Mar; 51(3):281-9. PubMed ID: 26314837
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The molecular basis for current targets of NASH therapies.
    Qureshi K; Neuschwander-Tetri BA
    Expert Opin Investig Drugs; 2020 Feb; 29(2):151-161. PubMed ID: 31847612
    [No Abstract]   [Full Text] [Related]  

  • 60. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Watanabe S; Hashimoto E; Ikejima K; Uto H; Ono M; Sumida Y; Seike M; Takei Y; Takehara T; Tokushige K; Nakajima A; Yoneda M; Saibara T; Shiota G; Sakaida I; Nakamuta M; Mizuta T; Tsubouchi H; Sugano K; Shimosegawa T; ;
    J Gastroenterol; 2015 Apr; 50(4):364-77. PubMed ID: 25708290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.